Overview of approved CAR-T products and utility in clinical practice
By Shakthi T Bhaskar, Bhagirathbhai Dholaria & 3 more. Since the first (CAR) T-cell product received FDA approval in 2017, studies have been completed that have led to approvals of CAR T-cells to treat a variety of malignancies.
Authors
- Shakthi Bhaskar (ORCID: https://orcid.org/0000-0003-4528-6367)
- Olalekan O. Oluwole (ORCID: https://orcid.org/0000-0001-8525-9641)
- Bhagirathbhai Dholaria (ORCID: https://orcid.org/0000-0003-2371-3655)
- Salyka Sengsayadeth
- Bipin N. Savani (ORCID: https://orcid.org/0000-0002-3304-9965)
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Hematology International
- Published
- 2024-10-23
- DOI
- https://doi.org/10.46989/001c.124277
- Citations
- 27
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 7.63